PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Authors:
- Amina BandaABAmina Banda
- Bastiaan M. PrivéBPBastiaan M. Privé
- Youssra AllachYAYoussra Allach
- Maike J. M. UijenMUMaike J. M. Uijen
- Steffie M. B. PetersSPSteffie M. B. Peters
- Cato C. LoeffCLCato C. Loeff
- Martin GotthardtMartin Gotthardt
- Constantijn H. J. MuselaersCMConstantijn H. J. Muselaers
- J. Alfred WitjesJWJ. Alfred Witjes
- Inge M. van OortIOInge M. van Oort
- J. P. Michiel SedelaarJSJ. P. Michiel Sedelaar
- Harm WestdorpHWHarm Westdorp
Open Access
Abstract
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [177Lu]Lu-PSMA- (177Lu-PSMA) or [225Ac]Ac-PSMA-radioligand treatment (225Ac-PSMA). In this retrospective study, we analyzed the safety and efficacy of PSMA-RLT in early-stage and hormone-sensitive metastatic prostate cancer patients. Methods: A retrospective study was performed in patients who received 177Lu-PSMA and/or 225Ac-PSMA with early-stage metastatic prostate cancer. The primary outcome parameter evaluated in this study was the progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcome parameters were prostate-specific antigen (PSA) response and the date of onset of CRPC state. Results: In total, 20 patients were included of which 18 patients received 177Lu-PSMA radioligand and two patients received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands. Patients received a median of 2 treatment cycles (range 1–6) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range (IQR) 5.2–7.4 GBq). PSMA-RLT was overall well-tolerated. The most common grade 1–2 side effects were xerostomia (n = 6) and fatigue (n = 8), which were only temporarily reported. One patient that received 225Ac-PSMA developed grade 3–4 bone marrow toxicity. The median PFS was 12 months (95% confidence interval (CI), 4.09–19.9 months). Seventeen (85%) patients had a ≥50% PSA response following PSMA-RLT. One patient developed CRPC 9 months following PSMA-RLT. Conclusions: In this small cohort study, PSMA-RLT appeared safe and showed encouraging efficacy for (metastasized) early-stage and hormone-sensitive prostate cancer patients. Prospective studies are awaited and should include long-term follow-up.Keywords
This publication has 42 references indexed in Scilit:
- Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancerOncotarget, 2017
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer ImagingJournal of Nuclear Medicine, 2016
- German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsJournal of Nuclear Medicine, 2016
- 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate CancerJournal of Nuclear Medicine, 2016
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Journal of Clinical Oncology, 2016
- Alpha-PET with terbium-149: evidence and perspectives for radiotheragnosticsEJNMMI Radiopharmacy and Chemistry, 2016
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617Journal of Nuclear Medicine, 2016
- Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical TherapyJournal of Nuclear Medicine, 2016
- Androgen deprivation therapy: evidence‐based management of side effectsBJU International, 2013
- Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.2006